Product
Standard-of-Care
Aliases
SOC
3 clinical trials
7 indications
Indication
Acute Myeloid LeukemiaIndication
Acute Lymphoblastic LeukemiaIndication
Mixed Phenotype Acute LeukemiaIndication
Myelodysplastic SyndromeIndication
Therapy-Related Myelodysplastic SyndromeIndication
Aortic Valve StenosisIndication
HER2-positive Early Breast CancerClinical trial
A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic GraftStatus: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Randomized, Open-Label, Parallel Group Trial to Evaluate the Effect of ENAVOgliflozin Compared With Standard-of-Care on Reduction of Adverse Clinical Events and Cardiac Reverse Remodeling in Patients Who Underwent Transcatheter Aortic Valve ImplantationStatus: Not yet recruiting, Estimated PCD: 2025-12-01
Clinical trial
NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Trastuzumab-deruxtecan Versus Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-06-01